• AML: could pretransplant nutritional interventions improve OS?

    Findings from one of the largest studies of its kind.

  • AACR 2019—Gilteritinib improves survival in FLT3-mutated AML

    Data from the phase 3 ADMIRAL trial led to U.S. regulatory approval.

  • AML: pazopanib demonstrates limited efficacy in phase 2 study

    No significant reduction in BM microvessel density.

  • Elderly AML: intensive chemotherapy, decitabine offer similar OS

    Cytogenetic profile may help identify IC candidates.

  • sAML: underlying MPN tied to inferior post-transplant survival

    Significant increase in relapse in CMML and MPN.

  • ASCO-SITC 2019—High-dose NK cell infusions show benefit in myeloid malignancies

    Phase 2 data show antitumor, antiviral activity with multiple infusions after haploidentical SCT.

  • R/R AML: phase 2 results for FLAG intensified by mitoxantrone

    More than 7 in 10 patients achieved complete remission.

  • AML: add-on eltrombopag fails to benefit ICT in phase 2 trial

    More serious AEs in patients receiving eltrombopag.

  • Breast cancer survivors face excess risk for AML, MDS in French study

    Novel risks for ALL/LL and MM also identified.

  • AML/MDS: LEN/AZA regimen offers promise in post-transplant relapse

    Impressive responses, low-level toxicity.

  • R/R AML: binimetinib minimally effective in phase 2 trial

    9 out of 10 patients did not respond.

  • AML: FDA warns of enasidenib-associated differentiation syndrome

    Symptoms of life-threatening adverse effect going unrecognized.

  • ASH 2018 — Iron chelation therapy boosts EFS in lower-risk MDS

    Data from the TELESTO randomized phase 2 trial.

  • FDA approves gilteritinib for FLT3+ AML

    First monotherapy approved for this indication.

  • Load more